tiprankstipranks
Trending News
More News >
Mentice AB (SE:MNTC)
:MNTC

Mentice AB (MNTC) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Mentice AB

(Frankfurt:MNTC)

Rating:50Neutral
Price Target:
kr17.50
▲(8.70%Upside)
Mentice AB's overall stock score is impacted primarily by its financial performance, which reflects revenue growth but significant profitability challenges. Technical analysis indicates mixed signals with some bearish trends. Valuation concerns due to negative earnings and no dividend further weigh on the score. The absence of earnings call data and corporate events leaves these factors unaddressed.

Mentice AB (MNTC) vs. iShares MSCI Sweden ETF (EWD)

Mentice AB Business Overview & Revenue Model

Company DescriptionMentice AB (MNTC) is a global leader in medical simulation solutions, specializing in the development of high-fidelity virtual reality-based training systems for healthcare professionals. The company focuses primarily on endovascular procedures, offering products that help medical practitioners enhance their skills and improve patient outcomes. With a strong emphasis on innovation, Mentice provides a range of simulators designed to replicate real-life surgical scenarios, thus aiding in the education and training of surgeons and medical students worldwide.
How the Company Makes MoneyMentice AB generates revenue through the sale of its medical simulation solutions, which include high-tech simulators for various endovascular procedures. The company's primary revenue streams are derived from direct sales to healthcare institutions, including hospitals, medical universities, and training centers. Additionally, Mentice offers subscription-based software licenses and maintenance contracts, providing ongoing technical support and updates for their products. The company also partners with medical device manufacturers to develop integrated training solutions, which can further contribute to its revenue. These collaborations enable Mentice to offer customized training modules that complement specific medical devices, thereby enhancing its value proposition to customers.

Mentice AB Financial Statement Overview

Summary
Mentice AB demonstrates revenue growth, but faces significant profitability challenges with consistent net losses and negative profit margins. The balance sheet shows low leverage, reducing financial risk, yet negative return on equity is concerning. Cash flow generation is weak, especially in free cash flow, indicating potential difficulties in sustaining growth.
Income Statement
45
Neutral
Mentice AB's income statement shows mixed results. While there is a positive trend in revenue growth, with TTM revenue increasing by 3.04% from the previous year, profitability remains a concern. The company has consistently reported net losses, and the TTM net profit margin is negative at -7.11%. EBITDA margin stands at 5.90%, indicating some operational efficiency, but EBIT margin is negative, highlighting ongoing challenges in covering operating expenses.
Balance Sheet
55
Neutral
The balance sheet reflects a stable equity position with a debt-to-equity ratio of 0.18, indicating low leverage and reduced financial risk. However, the equity ratio has slightly decreased to 38.72%, suggesting a marginal decline in the proportion of assets financed by equity. The return on equity is negative, at -18.59%, due to ongoing net losses, which is a concern for shareholder value.
Cash Flow
50
Neutral
Mentice AB's cash flow statement reveals challenges in generating free cash flow, with a negative TTM free cash flow of -3.75 million. The operating cash flow to net income ratio is positive at -0.60, indicating some ability to convert income into cash flow. However, the free cash flow to net income ratio remains negative, suggesting difficulty in maintaining cash flow after capital expenditures.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
299.17M290.33M273.61M217.95M185.06M137.50M
Gross Profit
265.02M257.25M236.38M188.94M149.92M104.11M
EBIT
-14.99M-12.40M-679.00K-22.67M-18.51M-31.59M
EBITDA
17.65M18.30M28.87M266.00K1.44M-3.90M
Net Income Common Stockholders
-21.29M-18.42M-2.82M-30.66M-29.19M-13.09M
Balance SheetCash, Cash Equivalents and Short-Term Investments
40.55M53.59M59.12M47.28M12.70M48.75M
Total Assets
295.65M323.90M322.53M332.98M261.90M245.27M
Total Debt
20.75M9.14M9.56M16.68M14.70M11.51M
Net Debt
-19.80M-44.45M-49.56M-30.61M2.01M-37.24M
Total Liabilities
181.13M180.24M163.55M170.34M125.02M82.02M
Stockholders Equity
114.52M143.66M158.97M162.63M136.89M163.25M
Cash FlowFree Cash Flow
-3.75M1.48M29.53M1.85M-31.03M5.20M
Operating Cash Flow
12.67M17.92M36.52M14.91M-5.13M30.53M
Investing Cash Flow
-16.42M-16.44M-16.18M-32.28M-25.90M-24.97M
Financing Cash Flow
-11.16M-9.31M-7.05M48.99M-5.78M-3.98M

Mentice AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price16.10
Price Trends
50DMA
18.47
Negative
100DMA
20.89
Negative
200DMA
23.51
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
38.86
Neutral
STOCH
5.03
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Negative. The current price of 16.1 is below the 20-day moving average (MA) of 17.48, below the 50-day MA of 18.47, and below the 200-day MA of 23.51, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.86 is Neutral, neither overbought nor oversold. The STOCH value of 5.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MNTC.

Mentice AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
kr1.18B36.4310.11%2.53%-44.90%
62
Neutral
$11.80B10.08-7.46%2.99%7.37%-8.21%
55
Neutral
kr1.04B-5.61%13.66%-139.90%
53
Neutral
kr465.09M-19.17%-12.50%-783.92%
50
Neutral
€411.66M-17.16%17.75%18.05%
46
Neutral
kr254.23M-88.97%-0.61%54.19%
46
Neutral
kr1.04B-7.30%23.51%80.47%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:MNTC
Mentice AB
16.10
-11.60
-41.88%
SE:ACARIX
Acarix AB
0.24
-0.08
-25.55%
SE:BACTI.B
Bactiguard Holding AB
29.70
-38.90
-56.71%
SE:CRAD.B
C-Rad AB Class B
34.95
-7.20
-17.08%
SE:INTEG.B
Integrum AB Class B
21.80
-30.60
-58.40%
SE:SEDANA
Sedana Medical AB
10.50
-13.60
-56.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.